Press Releases

Back to previous page

ReGen Biologics Launches European Website

CMI™ Information now Available On-line in French, German, Italian, and Spanish

FRANKLIN LAKES, NJ -- September 30, 2005 -- ReGen Biologics, Inc. (OTC:RGBI), an orthopedic products company that develops, manufactures, and markets innovative tissue growth and repair products for the U.S. and global markets, announced today that the company has successfully expanded its corporate website to better serve physicians and patients in European markets where the ReGen CMI is marketed.

The CMI is a type I collagen implant designed to facilitate growth of new tissue to replace removed or missing meniscus tissue in the human knee.

Commenting on the launch, Gerald E. Bisbee, Jr., Ph.D., Chairman and Chief Executive Officer of ReGen Biologics, stated, “This is another milestone for ReGen as we further our plans to commercialize the CMI in Europe.  The European market represents an excellent sampling of the global market potential for the CMI with over 250,000 meniscal procedures performed last year, accounting for an estimated 15% of the worldwide CMI market.”  Bisbee continued, “The launch of the translated websites augments our current marketing efforts in these regions, such as the newly initiated physician education campaigns, designed to raise levels of awareness and bring additional surgeon interest to the product.”

About ReGen Biologics, Inc.
ReGen Biologics is an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets. ReGen's first product using its patented core technology is the CMI, which uses the body's own healing process to grow new tissue in the meniscus, and restore activity levels for patients with meniscus loss. The Company's Multicenter Pivotal Clinical Trial is the largest clinical trial ever conducted involving the human meniscus. The manufacturing module was submitted to the FDA in Q3 2004. The Company expects to conclude the PMA submission with the filing of the CMI clinical module in the second half of 2005.

ReGen is headquartered in Franklin Lakes, NJ and manufactures the CMI in its ISO Certified facility located in Redwood City, CA.  For more information on ReGen, visit www.regenbio.com.

Contacts:

ReGen Europe:
Thomas B. Fischer
ReGen Biologics AG
Appenzell, Switzerland
+41 (0) 79 500 79 54
thomas.fischer@regenbio.com

ReGen USA:
Brion Umidi
Chief Financial Officer
ReGen Biologics, Inc.
(201) 651-3515
bumidi@regenbio.com

Investor Relations:
Al Palombo
Cameron Associates
Investor Relations
(212) 245-8800 Ext. 209
al@cameronassoc.com